RU2016124545A - Композиция ненуклеозидного ингибитора обратной транскриптазы - Google Patents

Композиция ненуклеозидного ингибитора обратной транскриптазы Download PDF

Info

Publication number
RU2016124545A
RU2016124545A RU2016124545D RU2016124545D RU2016124545A RU 2016124545 A RU2016124545 A RU 2016124545A RU 2016124545 D RU2016124545 D RU 2016124545D RU 2016124545 D RU2016124545 D RU 2016124545D RU 2016124545 A RU2016124545 A RU 2016124545A
Authority
RU
Russia
Prior art keywords
composition
reverse transcriptase
nucleoside reverse
transcriptase inhibitor
nucleoside
Prior art date
Application number
RU2016124545D
Other languages
English (en)
Inventor
Майкл ЛОУИНДЖЕР
Адития С. ТАТАВАРТИ
Патрик Жюль МАРСАК
Кристин Дж.М. ПЛОЭДЖЕР
Джон М. БАУМАНН
Кори Дж. БЛУМ
Катрин Энн БРУКХАРТ
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of RU2016124545A publication Critical patent/RU2016124545A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016124545D 2013-11-22 2014-11-19 Композиция ненуклеозидного ингибитора обратной транскриптазы RU2016124545A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907537P 2013-11-22 2013-11-22
US61/907,537 2013-11-22
PCT/US2014/066281 WO2015077273A1 (en) 2013-11-22 2014-11-19 Composition of a non-nucleoside reverse transcriptase inhibitor

Publications (1)

Publication Number Publication Date
RU2016124545A true RU2016124545A (ru) 2017-12-27

Family

ID=53180083

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016124545A RU2661399C1 (ru) 2013-11-22 2014-11-19 Композиция ненуклеозидного ингибитора обратной транскриптазы
RU2016124545D RU2016124545A (ru) 2013-11-22 2014-11-19 Композиция ненуклеозидного ингибитора обратной транскриптазы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2016124545A RU2661399C1 (ru) 2013-11-22 2014-11-19 Композиция ненуклеозидного ингибитора обратной транскриптазы

Country Status (11)

Country Link
US (1) US20160287568A1 (ru)
EP (1) EP3071037A4 (ru)
JP (2) JP6387094B2 (ru)
KR (2) KR102601617B1 (ru)
CN (1) CN105722392B (ru)
AU (1) AU2014353177B2 (ru)
BR (1) BR112016011605A8 (ru)
CA (1) CA2929499C (ru)
MX (1) MX2016006645A (ru)
RU (2) RU2661399C1 (ru)
WO (1) WO2015077273A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211687T1 (hr) * 2015-12-02 2022-03-04 Merck Sharp & Dohme Corp. Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin
RU2729792C1 (ru) * 2019-07-29 2020-08-12 Акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" Способы повышения растворимости лекарственного средства на основе пиримидинового производного бензофенона

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
CA2608952A1 (en) * 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
CN101277682B (zh) * 2005-07-28 2015-07-29 Isp投资有限公司 无定形依发韦仑及其生产
WO2007045572A1 (en) * 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
RU2457841C2 (ru) * 2006-02-09 2012-08-10 Мерк Шарп Энд Домэ Корп. Полимерные композиции ингибиторов сетр
TW201414469A (zh) * 2006-03-20 2014-04-16 Vertex Pharma 對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物
WO2009069014A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Amorphous lamivudine and its preparation
EP3130396B1 (en) * 2009-03-27 2021-03-17 Bend Research, Inc. Spray-drying process
RU2435584C2 (ru) * 2009-10-28 2011-12-10 Закрытое Акционерное Общество "Фармфирма "Сотекс" Пролонгированная фармацевтическая композиция, лекарственная форма и способ ее изготовления (варианты)
PT2924034T (pt) * 2010-03-30 2017-01-06 Merck Canada Inc Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体

Also Published As

Publication number Publication date
KR20160079816A (ko) 2016-07-06
KR102601617B1 (ko) 2023-11-10
JP6387094B2 (ja) 2018-09-05
RU2661399C1 (ru) 2018-07-16
BR112016011605A2 (pt) 2017-08-08
CN105722392B (zh) 2019-07-23
WO2015077273A1 (en) 2015-05-28
AU2014353177A1 (en) 2016-05-05
CN105722392A (zh) 2016-06-29
KR20220158860A (ko) 2022-12-01
CA2929499C (en) 2019-01-08
AU2014353177B2 (en) 2018-03-15
JP2018193396A (ja) 2018-12-06
US20160287568A1 (en) 2016-10-06
EP3071037A1 (en) 2016-09-28
MX2016006645A (es) 2016-12-16
CA2929499A1 (en) 2015-05-28
EP3071037A4 (en) 2017-08-02
BR112016011605A8 (pt) 2023-04-25
JP2016537332A (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
LTPA2019506I1 (lt) Nenukleozidinės reversinės transkriptazės inhibitoriai
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3431475T3 (da) Faste former af en selektiv CDK4/6-hæmmer
DK3027618T3 (da) Polymorf af syk-hæmmere
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3786162T3 (da) Bipyrazolderivater som jak-inhibitorer
DK3071203T3 (da) Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
DK3640241T3 (da) Bromdomænehæmmere
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
BR302013004392S1 (pt) Configuração aplicada emmetal sanitário
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
UY4410S (es) Configuración aplicada a un refrigerador
DK3027750T3 (da) Biokatalytisk sammensætning
DK2965026T3 (da) Generering af slushice
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
DK3071053T3 (da) Præbiotisk sammensætning
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
DK2910535T3 (da) Sammensætning til anvendelse af ekspanderet perlit
RU2016124545A (ru) Композиция ненуклеозидного ингибитора обратной транскриптазы
DK3027594T3 (da) 2-benzoylaminobenzamidderivater som bcl-3-hæmmere
BR302013004447S1 (pt) Configuração aplicada a torneira sanitária